AccuPlace
During the COVID-19 global health crisis, scientists, researchers, and companies around the world raced to develop an effective vaccine. Remarkably, the first COVID-19 vaccines were tested, manufactured, and distributed in less than a year — a feat of science and logistics that shattered the previous record for vaccine development, which had been four years for the measles vaccine.
AccuPlace played a critical behind-the-scenes role in this unprecedented effort. The company partnered with leading biotechnology firms to manufacture test kits and support the rapid development of vaccines. Their precision pressure-sensitive labeling systems minimized the risk of contaminated air breaching during production, resulting in greater testing accuracy and consistency — both essential in the fight against a fast-moving global pandemic.
“AccuPlace’s machines have been designed, tested, and refined over many years, making us the ideal candidate to meet the unique challenge COVID-19 presented,” said Mike Terry, Global Sales Manager for AccuPlace. “In the midst of the pandemic, lives were on the line and billions of individuals across the world were desperate for a breakthrough. This was not the time for learning on the job. AccuPlace’s years of experience automating die-cut adhesive assembly was an invaluable asset.”
With cutting-edge technology, deep industry expertise, and the urgency of a global health emergency, AccuPlace helped enable biotechnology companies to accelerate development timelines and bring life-saving vaccines to market faster than ever before.
